Literature DB >> 19508160

The imperative of influenza vaccines for elderly individuals-an evolving story.

Gregory A Poland, Mark J Mulligan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19508160      PMCID： PMC2843138          DOI： 10.1086/599791

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  24 in total

1.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.

Authors:  A Podda
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

2.  Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents.

Authors:  L G Rudenko; N H Arden; E Grigorieva; A Naychin; A Rekstin; A I Klimov; S Donina; J Desheva; R C Holman; A DeGuzman; N J Cox; J M Katz
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.

Authors:  Iris de Bruijn; Ingo Meyer; Lisya Gerez; Jos Nauta; Katinka Giezeman; Bram Palache
Journal:  Vaccine       Date:  2007-11-12       Impact factor: 3.641

Review 4.  Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; D I Smith
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

5.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

6.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.

Authors:  Ann R Falsey; John J Treanor; Nadia Tornieporth; Jose Capellan; Geoffrey J Gorse
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

7.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Authors:  David Holland; Robert Booy; Ferdinandus De Looze; Peter Eizenberg; James McDonald; Jeff Karrasch; Maureen McKeirnan; Hatem Salem; Graham Mills; Jim Reid; Françoise Weber; Melanie Saville
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

8.  State-specific influenza vaccination coverage among adults--United States, 2006-07 influenza season.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-09-26       Impact factor: 17.586

9.  Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines.

Authors:  Suzanne E Ohmit; John C Victor; Esther R Teich; Rachel K Truscon; Judy R Rotthoff; Duane W Newton; Sarah A Campbell; Matthew L Boulton; Arnold S Monto
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

10.  Influenza virus resistance to antiviral agents: a plea for rational use.

Authors:  Gregory A Poland; Robert M Jacobson; Inna G Ovsyannikova
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079
View more
  3 in total

1.  Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.

Authors:  H Keipp Talbot; Michael T Rock; Casey Johnson; Lynda Tussey; Uma Kavita; Anita Shanker; Alan R Shaw; David N Taylor
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

Review 2.  Utilizing population variation, vaccination, and systems biology to study human immunology.

Authors:  John S Tsang
Journal:  Trends Immunol       Date:  2015-07-14       Impact factor: 16.687

3.  Transcriptomic signatures of cellular and humoral immune responses in older adults after seasonal influenza vaccination identified by data-driven clustering.

Authors:  Emily A Voigt; Diane E Grill; Michael T Zimmermann; Whitney L Simon; Inna G Ovsyannikova; Richard B Kennedy; Gregory A Poland
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.996
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.